Woburn, MA— Phospholipid nanosomes are small, uniform liposomes manufactured utilizing SuperFluids™ (supercritical fluids, critical or near-critical fluids with and without polar cosolvents such as ethanol).
SuperFluids™ are first used to solvate phospholipid raw materials, and then decompressed to form phospholipid nanosomes that can encapsulate hydrophilic molecules such as therapeutic proteins and siRNA. Hydrophobic therapeutics such as Taxol are co-solvated with phospholipids in SuperFluids™ that, when decompressed, form phospholipid nanosomes encapsulating them in lipid bilayers. Phospholipid nanosomes can also be used to co-encapsulate hydrophilic and hydrophobic drugs such as Tdp1 and Top1 inhibitors for drug resistant cancers.
Polymer nanospheres comprising of hydrophobic biodegradable copolymers are also by manufactured by SuperFluids™. These nanospheres can be used for the oral delivery of therapeutic proteins such as insulin, hydrophobic anticancer drugs and small molecules such as Δ9-THC as well as the controlled release of viral (HIV and influenza) and bacterial (anthrax) antigens for vaccines.